Selected News

SEATTLE, WA, January 27, 2025— Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the appointment of Dr. Luke Walker as Chief Medical Officer. Dr. Walker brings more than 20 years of hematology and clinical development experience […]

Series C financing co-led by Double Point Ventures and DCVC Bio Proceeds to support the clinical development of VivoVec™ derived in vivo CAR T cells SEATTLE, WA, January 14, 2025— Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells,

SEATTLE, WA, January 6, 2025—Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced that the Company will present at the 43rd Annual J.P. Morgan Healthcare Conference taking place January 13-16, 2025, in San Francisco, CA. Presentation Date/Time:

SEATTLE, WA, November 26, 2024 — Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf cell therapies that aim to realize the full reach and promise of CAR-T cells, today announced that members of management will participate in a fireside chat and 1×1 investor meetings at the 7th Annual Evercore ISI HealthCONx Conference,